celecoxib has been researched along with pioglitazone in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 11 (73.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Alaaeddine, R; Belal, ASF; Bruning, JB; Chua, BSK; El-Yazbi, AF; Elzahhar, PA; Frkic, RL; Ibrahim, TM; Ismail, A; Knape, T; Labib, H; Nassra, R; von Knethen, A; Wallner, N | 1 |
| Narang, RK; Pathania, S; Rawal, RK | 1 |
| Brunner, M; Gehrmann, M; Kremmer, E; Multhoff, G; Pfister, K; Reichle, A | 1 |
| Bing, G; Cass, WA; Choi, DY; Dragicevic, N; Hunter, RL; Kim, HC; Liu, M; Seifert, K; Sullivan, PG | 1 |
| DiBattista, AM; Dumanis, SB; Newman, J; Rebeck, GW | 1 |
| Chen, A; Cheng, AM; Chuang, MC; He, H; Liao, SL; Liu, YW; Sheha, H; Tighe, S; Yin, HY | 1 |
| Kiran, AVVVR; Krishnamurthy, PT; Kumari, GK | 1 |
2 review(s) available for celecoxib and pioglitazone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Role of sulphur-heterocycles in medicinal chemistry: An update.
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Antihypertensive Agents; Antineoplastic Agents; Chemistry, Pharmaceutical; Heterocyclic Compounds; Humans; Hypoglycemic Agents; Sulfur | 2019 |
13 other study(ies) available for celecoxib and pioglitazone
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Shooting three inflammatory targets with a single bullet: Novel multi-targeting anti-inflammatory glitazones.
Topics: Animals; Anti-Inflammatory Agents; Arachidonate 15-Lipoxygenase; Cyclooxygenase 2 Inhibitors; Drug Design; Humans; Ligands; Molecular Docking Simulation; PPAR gamma; Protein Binding; Thiazolidinediones | 2019 |
Differential up-regulation of cytosolic and membrane-bound heat shock protein 70 in tumor cells by anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Aspirin; Celecoxib; Cell Line, Tumor; Cell Membrane; Cell Survival; Cytoplasm; Cytosol; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Flow Cytometry; Fluorescein-5-isothiocyanate; Granzymes; HSP70 Heat-Shock Proteins; Humans; Immunoblotting; Immunotherapy; Insulin; Kinetics; Lactones; Models, Chemical; Neoplasms; Pioglitazone; Pyrazoles; Serine Endopeptidases; Sulfonamides; Sulfones; Thiazolidinediones; Up-Regulation | 2004 |
Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system.
Topics: Animals; Celecoxib; Cell Death; Corpus Striatum; Cyclooxygenase 2 Inhibitors; Dopamine; In Vitro Techniques; Inflammation; Lipopolysaccharides; Male; Microglia; Mitochondria; Nerve Degeneration; Neurons; Pioglitazone; PPAR gamma; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Insulin; Substantia Nigra; Sulfonamides; Thiazolidinediones | 2007 |
Identification and modification of amyloid-independent phenotypes of APOE4 mice.
Topics: Age Factors; Alzheimer Disease; Amyloid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apolipoprotein E4; Brain; Celecoxib; Cyclooxygenase 2 Inhibitors; Dendritic Spines; Disease Models, Animal; Female; Genotype; Humans; Hypoglycemic Agents; Ibuprofen; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neurons; Phenotype; Pioglitazone; Protein Processing, Post-Translational; Thiazolidinediones | 2016 |
Celecoxib and Pioglitazone as Potential Therapeutics for Regulating TGF-β-Induced Hyaluronan in Dysthyroid Myopathy.
Topics: Adult; Blotting, Western; Case-Control Studies; Celecoxib; Cells, Cultured; Cyclooxygenase 2 Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Graves Ophthalmopathy; Humans; Hyaluronic Acid; Male; Middle Aged; Myoblasts; Oculomotor Muscles; Pioglitazone; PPAR gamma; Real-Time Polymerase Chain Reaction; Thiazolidinediones; Transforming Growth Factor beta | 2016 |
Preliminary evaluation of anticancer efficacy of pioglitazone combined with celecoxib for the treatment of non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Pioglitazone; PPAR gamma; Survival Analysis; Tumor Burden | 2022 |